Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients.
Bispecific antibody
CAR T cell
Cytokine release syndrome
ICANS
Siltuximab
Tocilizumab
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
18
04
2023
accepted:
07
06
2023
medline:
24
7
2023
pubmed:
24
6
2023
entrez:
24
6
2023
Statut:
ppublish
Résumé
Cytokine release syndrome (CRS) is a common adverse event of CAR T cell or bispecific antibody (bsAb) therapy. Anti-IL6/IL6R drugs are used in the management of auto-immune diseases. Some reports showed increased risk of bacterial infection in this context. In onco-hematology, there are few data about the occurrence of infection after administration of an anti-IL6/IL6R for CRS. We retrospectively reviewed all consecutive patients treated in Gustave Roussy Cancer Campus between 2018 and 2021, who received anti-IL6/IL6R for CRS due to bsAb in phase I clinical trials or adoptive cellular therapy (ACT). We constituted a control group including all the patients treated in the same clinical trials or standard of care ACT, naïve of anti-IL6/IL6R. Fifty-two patients have been included. In the anti-IL6/IL6R group (n = 26), five patients developed a grade 2 to 5 infection within a month after anti-IL6/IL6R treatment, including two grade 5 infections. In the control group (n = 26), only one patient had a grade 3 infection. The two patients who had grade 5 infections were treated for diffuse large B cell lymphoma (DLBCL), one with bsAb and the other with CAR T cell. Fifty percent (3/6) of DLBCL patients who received an anti-IL6/IL6R presented an infection, one of which was a grade 5. In solid tumor patients treated with bsAb and anti-IL6/IL6R, only one patient (/9, 11%) developed a grade 2 viral infection. It seems that the use of anti-IL6/IL6R in CRS secondary to bsAb administration in solid tumors patients does not significantly increase the risk of infection, as opposed to DLBCL patients where secondary infection might be a concern.
Sections du résumé
BACKGROUND
Cytokine release syndrome (CRS) is a common adverse event of CAR T cell or bispecific antibody (bsAb) therapy. Anti-IL6/IL6R drugs are used in the management of auto-immune diseases. Some reports showed increased risk of bacterial infection in this context. In onco-hematology, there are few data about the occurrence of infection after administration of an anti-IL6/IL6R for CRS.
METHODS
We retrospectively reviewed all consecutive patients treated in Gustave Roussy Cancer Campus between 2018 and 2021, who received anti-IL6/IL6R for CRS due to bsAb in phase I clinical trials or adoptive cellular therapy (ACT). We constituted a control group including all the patients treated in the same clinical trials or standard of care ACT, naïve of anti-IL6/IL6R.
RESULTS
Fifty-two patients have been included. In the anti-IL6/IL6R group (n = 26), five patients developed a grade 2 to 5 infection within a month after anti-IL6/IL6R treatment, including two grade 5 infections. In the control group (n = 26), only one patient had a grade 3 infection. The two patients who had grade 5 infections were treated for diffuse large B cell lymphoma (DLBCL), one with bsAb and the other with CAR T cell. Fifty percent (3/6) of DLBCL patients who received an anti-IL6/IL6R presented an infection, one of which was a grade 5. In solid tumor patients treated with bsAb and anti-IL6/IL6R, only one patient (/9, 11%) developed a grade 2 viral infection.
CONCLUSION
It seems that the use of anti-IL6/IL6R in CRS secondary to bsAb administration in solid tumors patients does not significantly increase the risk of infection, as opposed to DLBCL patients where secondary infection might be a concern.
Identifiants
pubmed: 37354233
doi: 10.1007/s00280-023-04551-6
pii: 10.1007/s00280-023-04551-6
doi:
Substances chimiques
Antibodies, Bispecific
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
229-233Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Kang S, Tanaka T, Narazaki M, Kishimoto T (2019) Targeting interleukin-6 signaling in clinic. Immunity 50:1007–1023. https://doi.org/10.1016/j.immuni.2019.03.026
doi: 10.1016/j.immuni.2019.03.026
pubmed: 30995492
Drug Approval Package: ACTEMRA (tocilizumab). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/125276Orig1s114TOC.cfm . Accessed 16 Jan 2022
SYLVANT (siltuximab). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125496Orig1s000TOC.cfm . Accessed 16 Jan 2022
Lin C-T, Huang W-N, Hsieh C-W et al (2019) Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis—a three-year study in Taiwan. J Microbiol Immunol Infect 52:141–150. https://doi.org/10.1016/j.jmii.2017.04.002
doi: 10.1016/j.jmii.2017.04.002
pubmed: 28734675
Schiff MH, Kremer JM, Jahreis A et al (2011) Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 13:R141. https://doi.org/10.1186/ar3455
doi: 10.1186/ar3455
pubmed: 21884601
pmcid: 3308069
Moore JB, June CH (2020) Cytokine release syndrome in severe COVID-19. Science. https://doi.org/10.1126/science.abb8925
doi: 10.1126/science.abb8925
pubmed: 33159009
pmcid: 7857411
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19|NEJM. https://doi.org/10.1056/NEJMoa2100433 . Accessed 8 May 2022
Rosas IO, Bräu N, Waters M et al (2021) Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. https://doi.org/10.1056/NEJMoa2028700
doi: 10.1056/NEJMoa2028700
pubmed: 34407336
pmcid: 7953459
Salama C, Han J, Yau L et al (2020) Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. https://doi.org/10.1056/NEJMoa2030340
doi: 10.1056/NEJMoa2030340
pubmed: 33332779
pmcid: 7781101
Pettit NN, Nguyen CT, Mutlu GM et al (2020) Late onset infectious complications and safety of tocilizumab in the management of COVID-19. J Med Virol. https://doi.org/10.1002/jmv.26429
doi: 10.1002/jmv.26429
pubmed: 32790075
pmcid: 7436682
Kimmig LM, Wu D, Gold M et al (2020) IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. medRxiv. https://doi.org/10.1101/2020.05.15.20103531
doi: 10.1101/2020.05.15.20103531
pubmed: 32935118
pmcid: 7491533
Moore JL, Stroever SJ, Rondain PE, Scatena RN (2021) Incidence of secondary bacterial infections following utilization of tocilizumab for the treatment of COVID-19—a matched retrospective cohort study. J Glob Infect Dis 13:67–71. https://doi.org/10.4103/jgid.jgid_358_20
doi: 10.4103/jgid.jgid_358_20
pubmed: 34194172
pmcid: 8213077
Frigault MJ, Nikiforow S, Mansour MK et al (2020) Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19? Blood 136:137–139. https://doi.org/10.1182/blood.2020006216
doi: 10.1182/blood.2020006216
pubmed: 32457999
Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25:625–638. https://doi.org/10.1016/j.bbmt.2018.12.758
doi: 10.1016/j.bbmt.2018.12.758
pubmed: 30592986